Proximal versus distal diuretics in congestive heart failure

Massimo Nardone,Vikas S Sridhar,Kevin Yau,Ayodele Odutayo,David Z I Cherney

DOI: https://doi.org/10.1093/ndt/gfae058

IF: 7.1857

2024-02-29

Nephrology Dialysis Transplantation

Abstract:Abstract Volume overload represents a hallmark clinical feature linked to the development and progression of heart failure (HF). Alleviating signs and symptoms of volume overload represents a foundational HF treatment target that is achieved using loop diuretics in the acute and chronic setting. Recent work has provided evidence to support guideline-directed medical therapies, such as sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor (MR) antagonists, as important adjunct diuretics that may act synergistically when used with background loop diuretics in people with chronic HF. Furthermore, there is growing interest in understanding the role of SGLT2 inhibitors, carbonic anhydrase inhibitors, thiazide diuretics, and MR antagonists in treating volume overload in patients hospitalized for acute HF, particularly in the setting of loop diuretic resistance. Thus, the current review demonstrates that: 1) SGLT2 inhibitors and MR antagonists confer long-term cardioprotection in chronic HF patients but it is unclear if natriuresis or diuresis represents the primary mechanisms for this benefit, 2) SGLT2 inhibitors, carbonic anhydrase inhibitors, and thiazide diuretics increase natriuresis in the acute HF setting, but implications on long-term outcomes remain unclear and warrants further investigation, and 3) a multi-nephron segment approach, using agents that act on distinct segments of the nephron, potentiate diuresis to alleviate signs and symptoms of volume overload in acute HF.

urology & nephrology,transplantation

What problem does this paper attempt to address?

This paper aims to explore the different effects of using proximal and distal diuretics in patients with congestive heart failure (HF). Specifically, the paper focuses on the following issues:

1. The long - term cardioprotective effects of sodium - glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor (MR) antagonists in patients with chronic heart failure, and whether this protective effect is mainly achieved through natriuretic or diuretic mechanisms.
2. The role of SGLT2 inhibitors, carbonic anhydrase inhibitors, and thiazide diuretics in increasing natriuresis in the setting of acute heart failure, and the impact of these effects on long - term prognosis.
3. The multi - nephron segment approach, that is, the use of drugs acting on different nephron segments, how to enhance the diuretic effect to relieve the symptoms of volume overload in patients with acute heart failure.

By reviewing the existing physiological and clinical evidence, the paper evaluates the application of SGLT2 inhibitors, carbonic anhydrase inhibitors, thiazide diuretics, and MR antagonists in the management of heart failure and their roles as adjunctive diuretics in acute and chronic settings. In particular, the paper discusses how these drugs can effectively manage volume overload when treating patients with acute heart failure, especially in the case of loop diuretic resistance.